CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
In recent years, immunotherapies have emerged as a promising class of cancer drugs that harnesses the power of the immune system to fight cancer. But despite their life-saving potential, their effectiveness is limited: only 20 to 30 per cent of people with cancer benefit from them and some experience severe side effects without any therapeutic benefit.
The CCTG Patient Representative Committee is pleased to welcome Deb Clark who will support the Gynecologic Disease site committee. Deb lives in Regina and her journey began when her mom was diagnosed with ovarian cancer, now a 26-year cancer survivor. Deb supported her mom as her caregiver through three additional, primary cancers and was her husband’s caregiver when he had oral cancer.
The international study CCTG MAC29 (OptimICE-pCR) is investigating whether treatment with immunotherapy versus observation in people with early-stage triple-negative breast cancer (TNBC) who had a good response after initial treatment with chemotherapy and immunotherapy is really necessary.
The investigators want to determine if observation after surgery is as effective as completing 6 more months of immunotherapy in TNBC patients who have completed standard treatment including immunotherapy before surgery, and who have had a good response.
